United States - English - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - pemetrexed disodium hemipentahydrate (unii: f4gsh45r4c) (pemetrexed - unii:04q9aiz7no) - pemetrexed for injection is indicated: - in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (nsclc), with no egfr or alk genomic tumor aberrations. - in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous nsclc. - as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous nsclc whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. - as a single agent for the treatment of patients with recurrent, metastatic non-squamous, nsclc after prior chemotherapy. limitations of use: pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer [see clinical studies (14.1)] . pemetrexed for injection is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural me

United States - English - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - pemetrexed disodium hemipentahydrate (unii: f4gsh45r4c) (pemetrexed - unii:04q9aiz7no) - pemetrexed for injection is indicated: - in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (nsclc), with no egfr or alk genomic tumor aberrations. - in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous nsclc. - as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous nsclc whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. - as a single agent for the treatment of patients with recurrent, metastatic non-squamous, nsclc after prior chemotherapy. limitations of use: pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer [see clinical studies (14.1)] . pemetrexed for injection is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural me

United States - English - NLM (National Library of Medicine)

shilpa medicare limited - pemetrexed disodium hemipentahydrate (unii: f4gsh45r4c) (pemetrexed - unii:04q9aiz7no) - pemetrexed injection is indicated: - in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (nsclc), with no egfr or alk genomic tumor aberrations. - in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous nsclc. - as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous nsclc whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. - as a single agent for the treatment of patients with recurrent, metastatic non-squamous, nsclc after prior chemotherapy. limitations of use : pemetrexed injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer [see clinical studies (14.1)]. pemetrexed injection is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose d

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - pemetrexed as disodium hemipentahydrate - powder for concentrate for solution for infusion - pemetrexed as disodium hemipentahydrate 500 mg - pemetrexed - pemetrexed s.k. in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed s.k. in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed s.k. is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed s.k. is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate -

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pemetrexed disodium hemipentahydrate 30,21 mg/ml - eq. pemetrexed 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - pemetrexed disodium 30.21 mg/ml - pemetrexed

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pemetrexed disodium hemipentahydrate 30,21 mg/ml - eq. pemetrexed 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - pemetrexed disodium 30.21 mg/ml - pemetrexed

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.8 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer (nsclc),pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology.,pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; mannitol - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer (nsclc),pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology.,pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology after prior platinum-based chemotherapy.